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1035-134 Lipoproteins, Lipid Peroxides, and Soluble Selectln in 
Patients Undergoing Redo Coronary Artery Bypass 
Surgery 
Ion S. Jovin. Uwe Taborski, Angelika Jovin, Markus Sch0nburg, Wolfgang W. Ricken, 
Karln Schreiner, Ursula Kupfermann, Klaus Winekler, Wolf-Peter KI0vekom, Gert M011er- 
Berghaus, Yale University, New Haven, Connecticut, Kerckhoff.Klinik, Bad Nauheim, 
Germany. 
The number of redo coronary artery bypass graft (CABG) procedures is steadily increas- 
ing and it is estimated that they now make up to 10% of all CABG operations that are cur- 
rently performed. However, redo procedures are associated with increased morbidity and 
mortality and understanding the risk factors that lead to repeat procedures may help 
develop better strategies for treatment and may help delay or prevent these operations. 
We compared 53 patients (44 men and 9 women) undergoing redo CABG with two 
groups of age and sex-matched patients: patients who had undergone CABG in the past 
and who had no evidence of ischemia at the time of routine follow-up, and patients who 
were scheduled to undergo their first CABG. We compared plasma lipoproteins, lipid per- 
oxides, which are markers for the oxidative stress, and soluble E-selectin, a marker for 
inflammatory processes in the vessel wall, between the 3 groups using analysis of vari- 
ance. 
We found no significant variance in the plasma low-density lipoprotein(LDL) cholesterol 
levels or in the total cholesterol/high-density lipoprotein(HDL) cholesterol ratio (P=0.22 
and P=0.63, respectively) between the 3 groups. The level of lipoprotein(a), a particle 
that may play a dual role in atheroscleresis and thrombosis, varied significantly between 
the groups (P=0.001). The plasma lipid peroxides and soluble E-selectin levels also 
showed significant vadance between the groups (P=0.03 and P=0.009, respectively). 
Our data suggests that oxidative stress and inflammatory processes in the vascular wall 
may play important roles in the pathogenesis of coronary bypass graft atherosclerosis 
and may ultimately be associated with an increased risk for redo CABG. The presumed 
proatherosclerotic and prothrombotic]antifibrinolytic a tivity of lipoprotein(a) is probably 
another contributor to this process. 
1035-135 Bosentan: A Therapeutic Strategy for Severe Radial 
Artery Vasospaam 
Subodh Verma. Tara Hyder, Lawrence Ko, Mitesh V. Badiwala, Paul Fedak, Ren-Ke Li, 
Richard D. Weisel, Vivek Rao, Stephen E. Fremes, University of Toronto, Toronto, 
Ontario, Canada, 
Backaround: Radial arteries are increasingly used as conduits for coronary artery 
bypass graft surgery. Severe and protracted vasospam is a rare and potentially fatal 
complication of radial artery use. Recent evidence suggests that the potent vasoconstric- 
tor peptide, endothelin-1 lET-l) may mediate resistant vasospasm of the radial artery. 
We compared the vasodiiatory effects of the ETNB receptor antagonist, bosentan vs. 
papaverine and verapamil in human radial arteries contracted with ET-I. 
Methods and Results: Segments of human radial arteries (n=14) were obtained pedop- 
eratively from patients undergoing coronary artery bypass graft surgery. Vascular seg- 
ments were cut into rings (3-5 mm in length) and mounted in isolated tissue baths for 
isometric dose-response assessments. Following equilibration, tissues were stimulated 
with a vasospastic dose of ET-1 (10"aM) and concentration-response curves to bosentan 
(n=8), papavedne (n=9) and verapamil (n=9) constructed. Percent maximum relaxation 
(%Emax) and agonist-sensitivity (ECs0) values were compared between groups using 
repeated measures ANOVA. ET-1 caused marked and protracted contraction of radial 
artery segments. Bosentan evoked significantly greater maximum relaxation (%Emax 
93.3-+6.6) when compared to either papaverine (%Emax 68.4¢5.3) or verapamil (%Emax 
56.2-+4.7), p<0.01. Additionally, bosentan was a more potent in vasodilating radial arter- 
ies (EC50 2.4_+1.1 x 10 -7 M) when compared to papaverine (EC5o 4.2+~9.4 x 10 -6 M) or 
verapamil (EC50 3.1_+2.7 x 10 -6 M), p<0.01. 
Conclusions: ET-1 has been implicated as an important mediator of severe radial artery 
vasospasm, We herein report, for the first time, the supedority of bosentan (compared to 
conventional agents) as a potent vasodilator of human radial artery segments contracted 
with vasospastic ET-1 concentrations. Bosentan may be an important pharmacological 
strategy for radial artery vasospasm. 
1035-136 Can Cardiac Operations Be Performed Safely in Liver 
Transplant Recipients? 
Harold M. Burkhart. Charles J. Mullany, Patrick S. Kamath, Richard C. Daly, Joseph A. 
Dearani, Thomas A. Orezulak, Hartzell V. Schaff, Kenton J. Zehr, Mayo Clinic and Mayo 
Foundation, Rochester, Minnesota. 
Background: Improved survival and widespread application of orthotopic liver transplan- 
tation has resulted in an increased number of liver transplant patients subsequently pre- 
senting for cardiac surgery. This study examines outcome of cardiac operations after 
previous orthotopio liver transplantation. 
Methods: From December 1993 to November 2000, eleven liver transplant patients (7 
men, 4 women) underwent cardiac operations. Median age was 61 years (range, 29 to 
71). The majority (91%) was in New York Heart Association functional class III or IV. Risk 
factors included hypertension (73%), chronic renal insufficiency (55%), and diabetes 
(36%). The median left ventricular ejection fraction was 0.60 (range, 0.30 to 0.70). Car- 
diac operations included coronary artery bypass grafting in 5 patients, valve replacement 
or repair in 4, and combined valve replacement and coronary artery bypass grafting in 2. 
Median time interval from liver transplantation to cardiac surgery was 6.6 years (range, 
1.1 to 12.1). 
Results: There were no early deaths. Major complications occurred in three patients and 
included ventilator dependence requiring temporary tracheostomy in 2 patients, septice- 
mia in 1, adult respiratory distress syndrome in 1, and a leg wound hematoma requiring 
operative drainage in 1. Average perioperative blood transfusion requirements were 
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three units (range, 0 to 7). Transient elevations in liver function parameters occurred in 
five patients. There were no episodes of hepatic rejection. FoUow-up was complete in all 
11 patients (median 12.2 months, range, 7.8 to 83.5). There were two late deaths sec- 
ondary to non-cardiac causes. 
Conclusion: Cardiac surgery can be performed safely in liver transplant recipients. In our 
limited experience, the intermediate-term results are good with low eady mortality and no 
major hepatic complications. Perioperative morbidity appears higher than in non-trans- 
plant recipients. 
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1036MP-121 LV Remodeling Following Aortic Valve Replacement fo r  
Aortic Stenosia in the Elderly 
Gerard P. Audoemma. Andrea Sweeney-Walsh, Robert Lancey, Alan Ronen, Dennis A. 
Tighe, Theo E. Meyer, University of Massachusetts Medical School, Worcester• 
Massachusetts. 
Background: Older studies of LV remodeling following valve replacement (AVR) for aor- 
tic stenosis (AS) have shown substantial reductions in LV mass. However the relevance 
of these findings for pts who are seen in current clinical practice, who are older, in whom 
LV dilation is uncommon, and in whom hypertension (HTN) is prevalent, is uncertain. 
Methods: We reviewed pre- and post-op echos in 30 pts with pure AS, age 67 -+10; 
mean follow-up was 24 mos (range 6-56); 14/30 pts had coexistent HTN. Myocardial 
function was assessed by relating midwall shortening (FSmw,%) to peak systolic stress 
(oc, g/cm2). Results: Following AVR, mass and (;c fell (see Table) and there was little 
change in FSmw. However 17/30 pts had LV mass changes that were within t-609 of pre- 
op, well within the range of precision for M-mode LV mass calculations. Change in mass 
was related closely to preoperative mass: r=0.67, p<0.001. However, mass regression 
was not significantly different between groups when grouped by hypertension status, by 
prosthesis size or type, or interval between AVR and post-op echo. Only 5/30 had LV 
dilation on the baseline study. Summary/Conclusion: In older subjects, substantial, 
unequivocal LV mass reduction following AVR occurs, but in only 40% of pts. Many older 
pts experience modest mass reduction following AVR for AS. The magnitude of LV mass ' 
regression is related to the reduction in stress, but more closely to preop LV mass. 
Improvement in midwall shortening is marginal, despite significant reduction in afferload. 
PWTd (mm)l LVIDd (mm) LV Mass (g)'i RWT peak stress FSmw (%) 
(g/cm2)'i - 
pre-op 13+2 50+6 263±85 0.52+0.04 309-+83 20+_3 
post-op 11_+2 48+5 219±62 0.50+_0.04 248_+64 21+_3 
LVIDd and PWTd are diastolic dimension and wall thickness, RWT=relative wall 
thickness 1" = p<0.05 by unpaired t-test 
12:12 p.m. 
1036MP-122 The Rate of Hemodynamic Progression Is Strongly 
Predictive of  Cl in ical  Outcome Mostly in Mild and 
Moderate Aortic Stenosis 
Francasco Antonini-Canterin. Andrea Erlicher, Eugenio Cervesato, Rita Piazza, PompUio 
Faggiano, Anna Gualeni, Cristina Romeo, Daniela Pavan, Gianluigi Nicolosi, A.R.C., 
Pordenone, its/y, Ospedale, Bolzano, Italy, 
Background. It has been recently reported that in patients with asymptomatic aortic 
stenosis (AS) a faster rate of hemodynamic progression is associated with a worse prog- 
nosis. The published studies however are limited by the small number of patients and by 
the short duration of follow-up. Furthermore little is known about the long-term outcome 
in mild and moderate AS. Methods. We analyzed from our echocardiographic database 
(1988-2000) all adult patients with an initial peak aortic velocity >2 m/s and with at least 
two echo examinations >6 months one apart of the other. Patients with pre-existing pros- 
thesis and/or aortic regurgitation more than moderate were excluded. The study popula- 
tion includes 1040 patients (544 males, 496 females; mean age 67_+11 years) followed 
for 45_+32 months (range 6-140 months), each one with 4_+3 echocardiograms. According 
to the first maximum Doppler velocity patients were divided into 3 groups: A) Mild AS 
(velocity <3 m/s): 550 patients; B) Moderate AS (velocity 3-3.9 m/s): 304 patients; C) 
Severe AS (velocity >3.9 m/s): t 86 patients. Results. Mean increase of jet Doppler veloc- 
ity was 0.15i-0.29 m/s/y in the entire population, 0.12i.-0.28 in group A, 0.22_+0.28 in 
group B, 0.15-z0.34 in group C (p<0.001). Overall mean reduction of aortic valve area 
was 0.07-+-0.10 cm2/y; 0.07:t:0.12 in group A, 0.08-+-0.09 in group B, 0.06-+0.10 in group C 
(p<0.01). A rapid progression (>0.3 m/s/y) was found in 19.6% of patients (13.4% in 
group A, 28.3% in group B and in 23.7% in group C; p<0.001). Dudng follow-up major 
clinical end points (cardiac death or aortic valve replacement) were observed in 39. t% of 
patients (8.7% in group A, 38.5% in group B, 88.3% in group C; p<0.001). Patients with 
faster progression had more clinical end points (55.2% vs 22.2% in the entire population, 
p<0.001; 28.4% vs 5.7% in group A, p<O.CO1; 61.6% vs 29.4% in group B, p<0.O01; 
72.7% vs 66.9% in group C, pans). Conclusion. Our study demonstrates in a large series 
of patients that hemodynamic progression is faster in moderate AS than in mild and 
